Dagmar Kubitza und Michael Becka - Info zur Person

(1 - 10 von 12

)

Effects of renal impairment on the pharmacokinetics, pharmacodynamics...

www.science-open.com

... Michael Becka, Atef Halabi, Volkmar Lufft, Dagmar Kubitza, Thomas Sign in using LinkedIn | Sign in using Facebook | Sign in using ...

Acknowledgement to Referees | SpringerLink

link.springer.com

Wolfgang Mueck, Jan Stampfuss, Dagmar Kubitza, Michael Becka. [http://link.springer.com/article s ]. Liraglutide in ...

Randomized, Double-Blind, Crossover Study to Investigate the Effect...

link.springer.com

Dagmar Kubitza,1 Wolfgang Mueck1 and Michael Becka2. 1 Clinical Department of Biometry, Pharmacometry, Bayer HealthCare AG, Wuppertal, Germany.

Body weight has limited influence on the safety, tolerability ...Gale

go.gale.com

von D Kubitza · · Zitiert von: 397 — Gale Academic OneFile includes Body weight has limited influence on the safety, tolera by Dagmar Kubitza, Michael Becka, Michael . Click to explore.

Dagmar Kubitza

www.infona.pl

Michael Becka · Drug Safety 31 , 1 , Background: ...

Clinical Pharmacokinetic and Pharmacodynamic CyberLeninkacyberleninka.org › article

cyberleninka.org

Similar topics of scientific paper in Clinical medicine , author of scholarly article — Wolfgang Mueck, Jan Stampfuss, Dagmar Kubitza, Michael Becka.

Exploratory evaluation of pharmacodynamics, pharmacokinetics and ...moh-it.pure.elsevier.com › publications › fingerprints

moh-it.pure.elsevier.com

Dagmar Kubitza, Stefan Willmann, Michael Becka, Kirstin Thelen, Guy Young, Leonardo R. Brandão, Paul Monagle, Christoph Male, Anthony Chan, Gili Kennet , ...